3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
112
Breast Neoplasms
87
Carcinoma, Non-Small-Cell Lung
85
Glioblastoma
72
Ovarian Neoplasms
62
Brain Neoplasms
45
Lung Neoplasms
41
Glioma
41
Fallopian Tube Neoplasms
41
Neoplasms
38
Colonic Neoplasms
34
Gliosarcoma
33
Carcinoma, Renal Cell
32
Rectal Neoplasms
31
Neoplasm Metastasis
29
Pancreatic Neoplasms
19
Carcinoma, Hepatocellular
19
Melanoma
18
Adenocarcinoma of Lung
18
Astrocytoma
15
Kidney Neoplasms
13
Stomach Neoplasms
12
Prostatic Neoplasms
12
Uterine Cervical Neoplasms
11
Oligodendroglioma
11
Liver Neoplasms
11
Esophageal Neoplasms
11
Sarcoma
10
Adenocarcinoma, Bronchiolo-Alveolar
10
Central Nervous System Neoplasms
9
Interventions
Sunitinib
2
Paclitaxel
2
valrubicin
1
temsirolimus
1
sipuleucel-T
1
luprolide acetate gel depot
1
ferumoxtran-10
1
abiraterone
1
abemaciclib
1
Suspensions
1
Surveys and Questionnaires
1
Standard of Care
1
Radiotherapy
1
Prednisone
1
Prednisolone
1
Powders
1
Pemetrexed
1
Neoadjuvant Therapy
1
National Cancer Institute (U.S.)
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Leuprolide
1
Fatty Acids, Omega-3
1
Educational Status
1
Docetaxel
1
Bevacizumab
1
Atorvastatin
1
Administration, Intravesical
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urogenital Neoplasms
×
Bevacizumab
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts